Skip to main content

Advertisement

SpringerLink
Log in

P-glycoprotein expression is induced in human pancreatic cancer xenografts during treatment with a cell cycle regulator, mimosine

  • Article
  • Published:
Pathology & Oncology Research

Abstract

Application of several cell cycle checkpoint regulators seem to be promising in various experimental models including pancreatic cancer, and they are being evaluated in Phase I–II clinical trials. Among these compounds, mimosine, a plant-derived amino acid has shown an antineoplastic effect on human lung or pancreatic cancer xenografts in addition to cell cycle arrest in the late G1 phase. In the present study, immunosuppressed CBA mice bearing subcutaneously growing human ductal pancreatic adenocarcinomas were treated with 30 mg/kg L-mimosine for 34 days. The treatment resulted in retardation of tumor growth, accompanied by a significantly diminished proliferative activity (22.6% ± 1.7% Ki-67 positivity vs. 29.9% ±1.1% in controls, mean ± SEM, P < 0.007) and an increased apoptotic rate (14.5 ± 1.1 apoptotic cells/mm2 vs. 3.8 ± 0.4/mm2 in the controls, P < 0.0001). The immunohistochemical expression of the multidrug resistance gene (MDR1)-encoded P-glycoprotein (p170) was studied. The parental and the untreated tumors did not express p170 protein, but in the mimosine-treated samples 30 to 60% of the carcinoma cells displayed a linear, membranebound positivity. The results indicate that P-glyco-protein is inducible by a cell cycle regulator, creating an acquired resistant phenotype.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abe S, Kubota T, Otani Y, et al: UCN-01 (7-hydroxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery. Jpn J Cancer Res 92: 537–545, 2001.

    PubMed  CAS  Google Scholar 

  2. Abolhoda A, Wilson AE, Ross H, et al: Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 5: 3352–3356, 1999.

    PubMed  CAS  Google Scholar 

  3. Bocsi J, Zalatnai A: Establishment and long term xenografting of human pancreatic carcinomas in immunosuppressed mice: Changes and stability in morphology, DNA ploidy and proliferative activity. J Cancer Res Clin Oncol 125: 9–19, 1999.

    Article  PubMed  CAS  Google Scholar 

  4. Buolamwini JK: Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Des 6: 379–392, 2000.

    Article  PubMed  CAS  Google Scholar 

  5. Chang HC, Lee TH, Chuang LY, et al: Inhibitory effect of mimosine on proliferation of human lung cancer cells is mediated by multiple mechanisms. Cancer Lett 145: 1–8, 1999.

    Article  PubMed  CAS  Google Scholar 

  6. Chang HC, Weng CF, Yen MH, et al: Modulation of cell cycle regulatory protein expression and suppression of tumor growth by mimosine in nude mice. Int J Oncol 17: 659–665, 2000.

    PubMed  CAS  Google Scholar 

  7. Chaudhary PM, Roninson IB: Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85: 632–639, 1993.

    Article  PubMed  CAS  Google Scholar 

  8. Chung HC, Rha SY, Kim JH, et al: P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 42: 65–72, 1997.

    Article  PubMed  CAS  Google Scholar 

  9. Fardel O, Lecureur V, Daval S, et al: Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem 246: 186–192, 1997.

    Article  PubMed  CAS  Google Scholar 

  10. Feldman ST, Schönthal A: Negative regulation of histone H1 kinase expression by mimosine, a plant amino acid. Cancer Res 54: 494–498, 1994.

    PubMed  CAS  Google Scholar 

  11. Goldstein LJ, Galski H, Fojo A, et al: Expression of a multidrug resistance gene in human cancers. J Nati Cancer Inst 81: 116–124, 1989.

    Article  CAS  Google Scholar 

  12. Granzotto M, Drigo I, Candussio L, et al: Rifampicin and verapamil induce the expression of P-glycoprotein in vivo in Ehrlich ascites tumor cells. Cancer Lett 205: 107–115, 2004.

    Article  PubMed  CAS  Google Scholar 

  13. Jimenez RE, Zalupski MM, Frank JJ, et al: Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy. Cancer 86: 976–981, 1999.

    Article  PubMed  CAS  Google Scholar 

  14. Krude T: Mimosine arrests proliferating human cells before onset of DNA replication in a dose-dependent manner. Exp Cell Res 247: 148–159, 1999.

    Article  PubMed  CAS  Google Scholar 

  15. Lage H, Dietel M: Multiple mechanisms confer different drugresistant phenotypes in pancreatic carcinoma cells. J Cancer Res Clin Oncol 128: 349–357, 2002.

    Article  PubMed  CAS  Google Scholar 

  16. Leonard GD, Fojo T, Bates SE: The role of ABC transporters in clinical practice. Oncologist 8: 411–424, 2003.

    Article  PubMed  CAS  Google Scholar 

  17. Licht T, Fiebig HH, Brass KJ, et al: Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int J Cancer 49: 630–637, 1991.

    Article  PubMed  CAS  Google Scholar 

  18. Lu Z, Kleeff J, Shrikhande S, et al: Expression of the multidrugresistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas 21: 240–247, 2000.

    Article  PubMed  CAS  Google Scholar 

  19. Mealey KL, Barhoumi R, Burghardt RC, et al: Doxycycline induces expression of P glycoprotein in MCF-7 breast carcinoma cells. Antimicrob Agents Chemother 46: 755–761, 2002.

    Article  PubMed  CAS  Google Scholar 

  20. Monden N, Abe S, Hishikawa Y, et al: The role of P-glycoprotein in human gastric cancer xenografts in response to chemotherapy. Int J Surg Invest 1: 3–10, 1999.

    CAS  Google Scholar 

  21. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ: The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 3: 59–70, 2004.

    PubMed  CAS  Google Scholar 

  22. Ng IO, Lam KY, Ng M, et al: Expression of P-glycoprotein, a multidrug-resistance gene product, is induced by radiotherapy in patients with oral squamous cell carcinoma. Cancer 83: 851–857, 1998.

    Article  PubMed  CAS  Google Scholar 

  23. Nielsen D, Eriksen J, Maare C, et al. P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicin. Br J Cancer 78: 1175–1180, 1998.

    PubMed  CAS  Google Scholar 

  24. Owa T, Yoshino II, Yoshimatsu K, Nagasu T: Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 8: 1487–1503, 2001.

    PubMed  CAS  Google Scholar 

  25. Ruiz van Haperen VW, Veerman G, Eriksson S, et al. Induction of resistance to 2′,2′-dilluorodeoxycytidine in the human ovarian cancer cell line A2780. Semin Oncol 22(Suppl 11): 35–41, 1995.

    PubMed  CAS  Google Scholar 

  26. Sandor V, Bakke S, Robey RW, et al: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8: 718–728, 2002.

    PubMed  CAS  Google Scholar 

  27. Sandor V, Robbins AR, Robey R, et al. FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anticancer Drugs 11: 445–545, 2000.

    Article  PubMed  CAS  Google Scholar 

  28. Sato N, Ohta T, Kitagawa H, et al: FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol 24: 679–685, 2004.

    PubMed  CAS  Google Scholar 

  29. Schondorf T, Neumann R, Benz C, et al: Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines. Recent Results Cancer Res 161: 111–116, 2003.

    PubMed  Google Scholar 

  30. Sun D, Urrabaz R, Buzello C, Nguyen M: Induction of DNA ligase I by 1-beta-D-arabinosylcytosine and aphidicolin in Mia-PaCa human pancreatic cancer cells. Exp Cell Res 280: 90–96, 2002.

    Article  PubMed  CAS  Google Scholar 

  31. Suwa H, Ohshio G, Arao S, et al: Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis. Jpn J Cancer Res 87: 641–649, 1996.

    PubMed  CAS  Google Scholar 

  32. Thomas H, Coley HM: Overcoming multidrug resistance in cancer: an update on clinical strategy on inhibiting P-glycoprotein. Cancer Control 10: 159–165, 2003.

    PubMed  Google Scholar 

  33. Tomida A, Naito M, Tsuruo T: Acute induction of adriamycin-resistance in human colon carcinoma HT-29 cells exposed to a sublethal dose of adriamycin. Jpn J Cancer Res 86: 224–232, 1995.

    PubMed  CAS  Google Scholar 

  34. Tsvetkov LM, Russev GC, Anachkova BB: Effect of mimosine on DNA synthesis in mammalian cells. Cancer Res 57: 2252–2255, 1997.

    PubMed  CAS  Google Scholar 

  35. Wada M, Hosotani R, Lee JU, et al: An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl2 ratio in p53-mutated pancreatic cancer cells. Anticancer Res 18: 2559–2566, 1998.

    PubMed  CAS  Google Scholar 

  36. Wang G, Miskimins R, Miskimins WK: Mimosine arrests cells in G1 by enhancing the levels of p27(Kip1). Exp Cell Res 254: 64–71, 2000.

    Article  PubMed  CAS  Google Scholar 

  37. Wartenberg M, Fischer K, Hescheler J, Sauer H: Modulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by cell cycle inhibitors. Biochim Biophys Acta 1589: 49–62, 2002.

    Article  PubMed  CAS  Google Scholar 

  38. Watson PA, Hanauske-Abel HH, Flint A, Lalande M: Mimosine reversibly arrests cell cycle progression at the G1-S phase border. Cytometry 12: 242–246, 1991.

    Article  PubMed  CAS  Google Scholar 

  39. Zalatnai A: Epidermal growth factor receptor, somatostatin and bcl-2 in human pancreatic tumor xenografts. An immunohistochemical study. Pathol Oncol Res 5: 146–151, 1999.

    Article  PubMed  CAS  Google Scholar 

  40. Zalatnai A: Potential role of cell cycle synchronizing agents in combination treatment modalities of malignant tumors. In vivo 19: 85–91, 2005.

    PubMed  CAS  Google Scholar 

  41. Zalatnai A, Bocsi J: Mimosine, a plant-derived amino acid induces apoptosis in human pancreatic cancer xenografts. Anticancer Res 23: 4007–4010, 2003.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Faculty of Medicine, Hungary

    Attila Zalatnai

Authors
  1. Attila Zalatnai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Attila Zalatnai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zalatnai, A. P-glycoprotein expression is induced in human pancreatic cancer xenografts during treatment with a cell cycle regulator, mimosine. Pathol. Oncol. Res. 11, 164–169 (2005). https://doi.org/10.1007/BF02893393

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02893393

Key words

Search

Navigation